In cardiac hypertrophy models, these inhibitors suppress GSNOR ubiquitination and cardiac hypertrophy, maintain GSNOR protein levels, reduce abnormal protein S-nitrosylation, and improve cardiac function. This evidence concerns the gene ADH5 and cardiac hypertrophy.